Evidence map›Paper›PMID 39858468›Full record

ReviewBiomolecules2025

Importance of Modulating Kynurenic Acid Metabolism-Approaches for the Treatment of Dementia.

Halina Baran, Marcelin Jan Pietryja, Berthold Kepplinger

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Halina BaranKarl Landsteiner Research Institute for Neurochemistry, Neuropharmacology, Neurorehabilitation and Pain Therapy, 3362 Mauer-Amstetten, Austria.
Marcelin Jan PietryjaSt. Francis Herbarium, Monastery of the Franciscan Friars Minor, 40-760 Katowice, Poland.
Berthold KepplingerKarl Landsteiner Research Institute for Neurochemistry, Neuropharmacology, Neurorehabilitation and Pain Therapy, 3362 Mauer-Amstetten, Austria.

Funding

Austrian National Bank 12316 to HBAustrian NFB Life Science LS10-032 (to BK and HBFWF Austrian Science Fund P15371
6 · The paper itself

Abstract

In this article, we focus on kynurenic acid metabolism in neuropsychiatric disorders and the biochemical processes involved in memory and cognitive impairment, followed by different approaches in the fight against dementia. Kynurenic acid-a biochemical part of L-tryptophan catabolism-is synthesized from L-kynurenine by kynurenine aminotransferases. Experimental pharmacological studies have shown that elevated levels of kynurenic acid in the brain are associated with impaired learning and that lowering kynurenic acid levels can improve these symptoms. The discovery of new compounds with the ability to block kynurenine aminotransferases opens new therapeutic avenues for the treatment of memory impairment and dementia. The newly developed

Indexed as

DementiaKynurenic AcidAnimalsBrainHumansKynurenineTransaminasesKynurenic AcidKynureninekynurenine-oxoglutarate transaminaseTransaminasesanti-dementia drugbird droppingscerebrolysinD-cycloserinedementiaglial depressing factorHelix pomatia snailherbsJerusalem Balsamkynurenic acidmemory modelplaquexanthurenic acid

Identifiers

PMID39858468
PMCPMC11764436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.